BioSpace News Archive

Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Needham Virtual Epilepsy and Pain Specialty CNS Therapeutics Conference

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that clinical proof-of-concept in patients with sickle cell disease (SCD) has been observed in the ongoing randomized, placebo-controlled, multi-center Phase 1 trial of FT-4202.

Saphena Medical, makers of Venapax, unitary endoscopic vessel harvesting system, announced today that it has been awarded a contract with Premier’s highly committed ASCEND (Accelerated Supply Chain Endeavor) program in the category of Endoscopic Vessel Harvesting. Premier Inc. is one of the largest performance improvement companies in the U.S.

Arcturus Therapeutics Holdings Inc., a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, announced the pricing of an underwritten public offering of 1,365,000 shares of its common stock at a public offering price of $110.00 per share.